Elanco Animal Health (NYSE:ELAN) Insider Shiv O’neill Purchases 3,998 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) insider Shiv O’neill bought 3,998 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average cost of $23.58 per share, with a total value of $94,272.84. Following the acquisition, the insider directly owned 87,832 shares in the company, valued at $2,071,078.56. This trade represents a 4.77% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Elanco Animal Health Price Performance

ELAN stock traded up $0.02 during trading on Tuesday, reaching $23.63. The company’s stock had a trading volume of 5,080,159 shares, compared to its average volume of 5,750,406. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The company’s fifty day moving average is $24.56 and its 200-day moving average is $24.01. The company has a market capitalization of $11.80 billion, a P/E ratio of -57.63, a price-to-earnings-growth ratio of 1.42 and a beta of 1.67. Elanco Animal Health Incorporated has a 1 year low of $17.11 and a 1 year high of $27.98.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Elanco Animal Health in the 2nd quarter worth approximately $1,202,198,000. Primecap Management Co. CA purchased a new stake in Elanco Animal Health during the 2nd quarter valued at $1,118,402,000. The Manufacturers Life Insurance Company bought a new stake in Elanco Animal Health in the second quarter worth $205,636,000. UBS Group AG boosted its stake in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after buying an additional 5,961,457 shares during the period. Finally, Sei Investments Co. boosted its stake in Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after buying an additional 4,975,721 shares during the period. 97.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ELAN. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Morgan Stanley raised their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. UBS Group upped their price target on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, KeyCorp increased their price objective on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.